Introduction Impulsivity, compulsivity, and addiction correlate with each other. Addiction is a process that coordinates the transition from impulsive to compulsive behavior; therefore, Impulsivity occurs during the early stages of addiction when a person acts impulsively on powerful urges to experience the pleasure of their addiction whereas compulsive aspect of addiction takes place when the shift occurs causing a person to no longer pursue their addiction solely for pleasure but compels the person to participate in their addiction to relieve anxious or uncomfortable feelings (Horvath, Misra, Epner, Cooper, 2015). According to Stahl (2013), impulsivity and compulsivity simply means that they are both symptoms that result from the brain not being able to say “no.” The case study for this assignment is on a 53-year-old Puerto Rican female who presents to the clinic due to a rather “embarrassing problem” with alcohol addiction since her 20’s after her father passed away. Client reports being involved with Alcohol Anonymous “on and off” for the past 25 years, and having difficulty maintaining her sobriety which has gotten worse for the past two years due to battling with gambling addiction after a casino was opened near her home which in turn increased her cigarette smoking and she is concerned about the negative effects of the cigarette smoking on her health. The purpose of this paper is to show how to assess and develop personalized therapy plans for clients with impulsivity, compulsivity, and addiction based on the decision concerning the medication to prescribe to the client, the influence of pharmacokinetic and pharmacodynamic, and including ethical and legal implications related to prescribing therapy for clients with impulsivity, compulsivity, and addiction. Decision One The first decision selected is to start the client on Naltrexone (Vivitrol) injection, 380 mg intramuscularly in the gluteal region every four weeks. Naltrexone is commonly prescribed for alcohol dependence and works by reducing alcohol consumption through modulation of opioid systems, thereby reducing the reinforcing effects of alcohol (Stahl, 2014b). In 2006, FDA approved the was development of Naltrexone injection to address the problem of compliance
Order this paper